Free Newsletter
Artificial molecules cure cirrhosis in animal study
Japanese scientists have found a way to deliver a payload of artificial molecules designed to prevent cells from secreting collagen, possibly pointing to a new approach to treating cirrhosis that could be commercialized in just a few years. In a study involving rats, the research team created artificial molecules that blocked the creation of collagen in liver stellate cells. The molecules were wrapped in vitamin A so that the stellate cells would absorb the molecules, allowing the therapy to work. Cirrhosis--a hardening or scarring of tissue--is caused by heavy drinking as well as hepatitis C and B. Yoshiro Niitsu at the Sapporo Medical University School of Medicine in Japan said the approach cured cirrhosis in rats.
"We want to carry out clinical tests with private companies and put this to practical use within five years," one of the researchers told AFP by telephone.
- read the AFP report
Comments
Recent advances have shown that natural safe treatments an admixture of homeopathic remedies and sarcodes help in arresting the process of cirrhosis.* Biogetica provides such therapy kits (LPS2, T15), the ingredients in the kit clear the liver of all the accumulated toxins.* They provide sarcode support to the liver, coaxing it into optimal functioning.* To a certain extent, they also help in regeneration of liver tissue.* These therapies are free of toxins and are ideally suited to effectively manage liver affections.
yea will even if it works in humans it will never be used because they do not want to cure anything just treat symtoms
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: